Wolf O. Bechstein

Active 1988–2025

121
Papers
26,724
Citations
81
h-index
116
i10-index

Citations

Citations per year for Wolf O. Bechstein1939: 1 citations1986: 1 citations1989: 1 citations1990: 6 citations1991: 13 citations1992: 6 citations1993: 14 citations1994: 12 citations1995: 11 citations1996: 31 citations1997: 37 citations1998: 41 citations1999: 42 citations2000: 50 citations2001: 48 citations2002: 54 citations2003: 53 citations2004: 66 citations2005: 58 citations2006: 69 citations2007: 90 citations2008: 116 citations2009: 121 citations2010: 143 citations2011: 138 citations2012: 152 citations2013: 122 citations2014: 140 citations2015: 111 citations2016: 109 citations2017: 142 citations2018: 116 citations2019: 641 citations2020: 770 citations2021: 753 citations2022: 559 citations2023: 426 citations2024: 818 citations2025: 354 citations2026: 7 citations1940–1985: no citations, so these years are not shown1987–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,775 citing papers, 19.6% of this breakdownChina: 841 citing papers, 9.3% of this breakdownGermany: 796 citing papers, 8.8% of this breakdownItaly: 618 citing papers, 6.8% of this breakdownUnited Kingdom: 581 citing papers, 6.4% of this breakdownJapan: 569 citing papers, 6.3% of this breakdownFrance: 463 citing papers, 5.1% of this breakdownNetherlands: 431 citing papers, 4.8% of this breakdownSpain: 287 citing papers, 3.2% of this breakdownCanada: 269 citing papers, 3% of this breakdownSwitzerland: 246 citing papers, 2.7% of this breakdownBelgium: 206 citing papers, 2.3% of this breakdown
0%19.6%Other 21.7%

Fields

  • Medicine90.1%
  • Biochemistry, Genetics and Molecular Biology5.9%
  • Immunology and Microbiology1.1%
  • Engineering0.7%
  • Materials Science0.7%
  • Physics and Astronomy0.3%
  • Other1.2%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis9%
  • Pancreatic and Hepatic Oncology Research6.2%
  • Gastric Cancer Management and Outcomes5.8%
  • Cholangiocarcinoma and Gallbladder Cancer Studies5.5%
  • Organ Transplantation Techniques and Outcomes3.9%
  • Colorectal Cancer Treatments and Studies3.6%
  • Other66%

Coauthors

All papers

Open in search
  1. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dirk Behringer, Michael Heike, Daniel Pink, Christian Teschendorf, Carmen Löhr, Helga Bernhard, Gunter Schuch, Volker Rethwisch, Ludwig Fischer von Weikersthal, Jörg T. Hartmann, Michael Kneba, S Daum, Karsten Schulmann, J. Weniger, Sebastian Belle, Timo Gaiser, Fuat Oduncu, Martina Güntner, Wael Hozaeel, Alexander Reichart, Elke Jäger, Thomas Kraus, Stefan Mönig, Wolf O. Bechstein, Martin Schüler, Harald Schmalenberg, Ralf‐Dieter Hofheinz - The Lancet 2019 cited by 2,583

  2. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2013 cited by 1,316

  3. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin‐Leo Hansmann, Peter J. Wild, Stephan Falk, Petra Hödl, A Serebrennikov, Sanja Schmeck, Vittorio Paolucci, Stephan Sahm, Martin Eichel, Giovanna Römer, W. Bank, Nicolas Moosmann, Jan Braess, P. Piso, Heinrich Wiesinger, Peter Kappl, Elisabeth Germer, Monika Warmuth‐Metz, Volker Kunzmann, Katica Krajinovic, Andreas Rosenwald, Thorsten Alexander Bley, Ulrich Stölzel, Manfred Dörne, L. Renziehausen, Joachim Boese-Land, Dietrich Meißner, D. Burchert, Olaf Dirsch, Jörg Olaf Habeck, Klaus Kirchhof, Christof Lamberti, B. J. Leibl, Andreas Gschwendtner, Godehard Lahmer, Marga Lang-Welzenbach, Werner Hohenberger, Thomas Kuhnt, Kirsten Papsdorf, Christian Wittekind, Christine Volkheimer, Frederik Wenz, Kirsten Merx, Stefan Post, Timo Gaiser, Ulrike Attenberger, Michael Geißler, Jörn Sträter, Helmut Gnann, Stefan Krämer, Michael Henke, Henning Schäfer, Philipp Manegold, Hannes Neeff, Peter Bronsert, Wolff Schmiegel, Michael Pohl, Christian Möllecken, Irenä us A. Adamietz, Richard Viehbahn, Andrea Tannapfel, Jens Freiberg‐Richter, Thorsten Jacobi, Wolfgang Wendt, Klaus Holzweißig, Thomas Kittner, Ullrich Graeven, Christiane Lange, U. Kania, Elisabeth Rösler and 28 more - JAMA Oncology 2021 cited by 354

  4. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 195

  5. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alfred Königsrainer, Timo Gaiser, Peter Schirmacher, Wael Hozaeel, Alexander Reichart, Thorsten Oliver Goetze, Mark Sievert, Elke Jäger, Stefan Mönig, Andrea Tannapfel - The Lancet Oncology 2016 cited by 739

  6. Colorectal Cancer Organoid–Stroma Biobank Allows Subtype-Specific Assessment of Individualized Therapy Responses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Florian R. Greten - Cancer Discovery 2023 cited by 109

  7. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 540

  8. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2017 cited by 474

  9. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial

    Authors: , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2017 cited by 678

  10. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Angela Schlitt, Susanne Beckebaum, Christian Graeb, Silvio Nadalin, Umberto Valente, Víctor Sánchez Turrión, Neville V. Jamieson, Tim Scholz, M. Colledan, Fred Fändrich, Thomas Becker, Gunnar Söderdahl, Olivier Chazouillères, Heikki Mäkisalo, Georges‐Philippe Pageaux, Rudolf Steininger, Thomas Soliman, Koert P. de Jong, Jacques Pirenne, Raimund Margreiter, Johann Pratschke, Antonio D. Pinna, Johann Hauss, Stefan Schreiber, Simone I. Strasser, Jürgen Klempnauer, Roberto Troisi, Sherrie Bhoori, Jan Lerut, Itxarone Bilbao, Christian Klein, Alfred Königsrainer, Darius F. Mirza, Gerd Otto, Vincenzo Mazzaferro, P. Neuhaus, Hans J. Schlitt - Transplantation 2015 cited by 417

  11. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - JAMA 2007 cited by 2,377

  12. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet 2008 cited by 1,945

  13. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 296

  14. Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - British journal of surgery 2021 cited by 100

  15. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 91

  16. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antonio Daniele Pinna, Jaques Pirenne, Johann Pratschke, James Powel, Markus Rentsch, Magnus Rizell, G. Rossi, Lionel Rostaing, André Roy, Tim Scholz, Utz Settmacher, Thomas Soliman, Simone I. Strasser, Gunnar Söderdahl, Roberto Troisi, Víctor Sánchez Turrión, Hans J. Schlitt, Edward K. Geissler - Annals of Surgery 2020 cited by 139

  17. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Zander, Hakan Alakus, Ralf‐Dieter Hofheinz, Claus Röedel, Manish A. Shah, Mitsuru Sasako, Dietmar Lorenz, Jakob R. Izbicki, Wolf O. Bechstein, Hauke Lang, Stefan Paul Moenig - BMC Cancer 2017 cited by 228

  18. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 114

  19. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer

    Authors: , , , , , , , , , , , , - Strahlentherapie und Onkologie 2014 cited by 330

  20. Toward a Consensus on Centralization in Surgery

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Surgery 2018 cited by 265

  21. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 cited by 714

  22. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

    Authors: , , , , , , , , , , , , , , , , , , , - Transplantation 2017 cited by 311

  23. Defining Major Surgery: A Delphi Consensus Among European Surgical Association (ESA) Members

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bertil Hamberger, J.F. Hamming, A. H. Hölscher, Jakob R. Izbicki, Sven Jonas, Aleksandar Karamarković, Henrik Kehlet, Ari Leppäniemi, Jan Lerut, Pål‐Dag Line, J. Peter A. Lodge, Jonathan Meakins, Marco Montorsi, Philippe Nafteux, Peter Naredi, Attila Oláh, Yves Panís, Fernando Pardo, Rowan W. Parks, Sergio Pedrazzoli, Patrick Pessaux, Hugo P. Marques, Gilberto Poggioli, Irinel Popescu, Pauli Puolakkainen, José Manuel Ramia, Jari Räsänen, John V. Reynolds, Riccardo Rosati, Hans‐Detlev Saeger, Stefan Schneeberger, Paul M. Schneider, Kjetil Søreide, Dirk L. Stippel, Christian Toso, Jean–Jacques Tuech, Erkki Tukiainen, Richard van Hillegersberg, Bas P. L. Wijnhoven, Desmond C. Winter, Giovanni Zaninotto - World Journal of Surgery 2020 cited by 91

  24. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2009 cited by 960